“BRILACIDIN [...] HAS A HIGH LIKELIHOOD OF REACHING COMMERCIALIZATION.”
With all the respect that’s due to Dr. Michael Zasloff, when it comes to drug development he obviously doesn’t know his ass from his elbow.
Even if IPIX had halfway reasonable management rather than the Krooked Keystone Kop kurrently in charge, its clinical history suggests it will never achieve a risk benefit ratio that would allow any regulatory authority anywhere in the world to let it onto the market.
"The saddest lessons of history is this: If we’ve been conned long enough, we reject any evidence of the con. It’s too painful to acknowledge, even to ourselves, that we’ve been taken. if you give a charlatan power over you, you never get it back.”